TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients

Journal of Clinical Investigation

Volumn 125, Issue 5, 2015, Pages 2046-2058

  Chauvin, Joe Marc ^a   Pagliano, Ornella ^a   Fourcade, Julien ^a   Sun, Zhaojun ^a   Wang, Hong ^b   Sander, Cindy ^a   Kirkwood, John M ^a   Chen, Tseng Hui Timothy ^c   Maurer, Mark ^c   Korman, Alan J ^c   Zarour, Hassane M ^a,d  

^a SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c Biologics Discovery California   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; PROGRAMMED DEATH 1 RECEPTOR; T CELL IMMUNOGLOBULIN AND ITIM DOMAIN; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG; CD226 ANTIGEN; CYTOKINE; IL2RB PROTEIN, HUMAN; IMMUNOGLOBULIN RECEPTOR; INTERLEUKIN 2 RECEPTOR BETA; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; POLIOVIRUS RECEPTOR; T LYMPHOCYTE ANTIGEN; TIGIT PROTEIN, HUMAN; TUMOR PROTEIN; VIRUS RECEPTOR;

ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEGRANULATION; EX VIVO STUDY; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; LYMPHOCYTIC INFILTRATION; METASTATIC MELANOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; UPREGULATION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; MELANOMA; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTIGEN-PRESENTING CELLS; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOKINES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; INTERLEUKIN-2 RECEPTOR BETA SUBUNIT; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; NEOPLASM PROTEINS; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, IMMUNOLOGIC; RECEPTORS, VIRUS; T-CELL ANTIGEN RECEPTOR SPECIFICITY; UP-REGULATION;

EID: 84929000784     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI80445     Document Type: Article

References (43)

1. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol. 2006;24:175-208.
2. Wherry EJ, Barber DL, Kaech SM, Blattman JN, Ahmed R. Antigen-independent memory CD8 T cells do not develop during chronic viral infection. Proc Natl Acad Sci U S A. 2004;101(45):16004-16009.
3. Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12(6):492-499.
4. Ahmadzadeh M, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114(8):1537-1544.
5. + T cell expansion in melanoma patients. J Immunol. 2009;182(9):5240-5249.
6. + T cell dysfunction in melanoma patients. J Exp Med. 2010;207(10):2175-2186.
7. Fourcade J, et al. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res. 2012;72(4):887-896.
8. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010;207(10):2187-2194.
9. Barber DL, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439(7077):682-687.
10. + T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2009;10(1):29-37.
11. Topalian SL, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020-1030.
12. Hamid O, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134-144.
13. Wolchok JD, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122-133.
14. Boles KS, et al. A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC. Eur J Immunol. 2009;39(3):695-703.
15. Stengel KF, et al. Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell-cell adhesion and signaling mechanism that requires cis-trans receptor clustering. Proc Natl Acad Sci U S A. 2012;109(14):5399-5404.
16. Yu X, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 2009;10(1):48-57.
17. Stanietsky N, et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci U S A. 2009;106(42):17858-17863.
18. Shibuya A, et al. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity. 1996;4(6):573-581.
19. Shibuya K, et al. CD226 (DNAM-1) is involved in lymphocyte function-associated antigen 1 costimulatory signal for naive T cell differentiation and proliferation. J Exp Med. 2003;198(12):1829-1839.
20. Fuchs A, Cella M, Giurisato E, Shaw AS, Colonna M. Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155). J Immunol. 2004;172(7):3994-3998.
21. Bottino C, et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med. 2003;198(4):557-567.
22. Tahara-Hanaoka S, et al. Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112). Int Immunol. 2004;16(4):533-538.
23. Mendelsohn CL, Wimmer E, Racaniello VR. Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell. 1989;56(5):855-865.
24. Freistadt MS, Fleit HB, Wimmer E. Poliovirus receptor on human blood cells: a possible extraneural site of poliovirus replication. Virology. 1993;195(2):798-803.
25. Kamran N, Takai Y, Miyoshi J, Biswas SK, Wong JS, Gasser S. Toll-like receptor ligands induce expression of the costimulatory molecule CD155 on antigen-presenting cells. PLoS One. 2013;8(1):e54406.
26. Reymond N, et al. DNAM-1 and PVR regulate monocyte migration through endothelial junctions. J Exp Med. 2004;199(10):1331-1341.
27. Tucker SP, Thornton CL, Wimmer E, Compans RW. Bidirectional entry of poliovirus into polarized epithelial cells. J Virol. 1993;67(1):29-38.
28. Lopez M, Aoubala M, Jordier F, Isnardon D, Gomez S, Dubreuil P. The human poliovirus receptor related 2 protein is a new hematopoietic/endothelial homophilic adhesion molecule. Blood. 1998;92(12):4602-4611.
29. Pende D, et al. Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killer-dendritic cell interaction. Blood. 2006;107(5):2030-2036.
30. Ardolino M, et al. DNAM-1 ligand expression on Ag-stimulated T lymphocytes is mediated by ROS-dependent activation of DNA-damage response: relevance for NK-T cell interaction. Blood. 2011;117(18):4778-4786.
31. Bevelacqua V, et al. Nectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanoma. Oncotarget. 2012;3(8):882-892.
32. Casado JG, et al. Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines. Cancer Immunol Immunother. 2009;58(9):1517-1526.
33. Oshima T, et al. Nectin-2 is a potential target for antibody therapy of breast and ovarian cancers. Mol Cancer. 2013;12:60.
34. Sloan KE, et al. CD155/PVR plays a key role in cell motility during tumor cell invasion and migration. BMC Cancer. 2004;4:73.
35. Joller N, et al. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J Immunol. 2011;186(3):1338-1342.
36. Levin SD, et al. Vstm3 is a member of the CD28 family and an important modulator of T-cell function. Eur J Immunol. 2011;41(4):902-915.
37. Lozano E, Dominguez-Villar M, Kuchroo V, Hafler DA. The TIGIT/CD226 axis regulates human T cell function. J Immunol. 2012;188(8):3869-3875.
38. Zhang Y, et al. Genome-wide DNA methylation analysis identifies hypomethylated genes regulated by FOXP3 in human regulatory T cells. Blood. 2013;122(16):2823-2836.
39. Joller N, et al. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity. 2014;40(4):569-581.
40. Johnston RJ, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell. 2014;26(6):923-937.
41. Fourcade J, et al. PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8(+) T cells induced by melanoma vaccines. Cancer Res. 2014;74(4):1045-1055.
42. Lonberg N, et al. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature. 1994;368(6474):856-859.
43. Fishwild DM, et al. High-avidity human IgGκ monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat Biotechnol. 1996;14(7):845-851.